Recent Updates
Recently added Catalysts

MACI

Phase 3

Chondral Defect | Monoclonal antibody | Other |Vericel Corporation|Last Updated: Dec 2, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment45
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03588975A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the KneePHASE3 RECRUITING 45Oct 24, 2018Jun 1, 2027Dec 2, 202412 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Proportion of Patients Who Achieve at Least a 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Scores
Baseline and Week 104

A responder is defined as a participant with at least a 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Secondary Endpoints
Change from Baseline in KOOS-Child subscores
Baseline and Week 104
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
MACIEXPERIMENTALautologous cultured chondrocytes on porcine collagen membrane
microfractureACTIVE_COMPARATORsurgical procedure
Interventions
NameTypeDescription
MACIBIOLOGICALautologous cultured chondrocytes on porcine collagen membrane
microfracturePROCEDUREArthroscopic microfracture treatment
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years — 17 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Symptomatic cartilage or osteochondral defects * One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determin...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT03588975primaryCompletionDate: changed
LOWMay 24, 2026NCT03588975studyFirstPostDate: changed